The data in Fig. 3B indicated that the proportion of CD4+IL-17+ Th17 cells was significantly higher in the HCC groups of early-stage (I–II) patients with various tumor sizes than in the control group; moreover, the proportion of CD4+IL-17+ Th17 cells was significantly higher in the HCC group of patients with large tumors than in the HCC group of patients with small tumors. The gene discussed is CD4; the disease is hepatocellular carcinoma.